Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evgeny Belyavskiy

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Therapeutics and Clinical Risk Management|September 9, 2020
Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and RecommendationsOlga Dzhioeva, Evgeny Belyavskiy
Reviews in Cardiovascular Medicine|July 30, 2024
Preoperative Stress Testing before Non-Cardiac SurgeryOlga Dzhioeva, Marijana Tadic, Evgeny Belyavskiy
Pharmacological Research|January 26, 2019
Intriguing relationship between antihypertensive therapy and cancerMarijana Tadic, Cesare Cuspidi, Evgeny Belyavskiy, et al.
Journal of Clinical Medicine|July 9, 2022
Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort StudyArtem Ovchinnikov, Evgeny Belyavskiy, Alexandra Potekhina, et al.
Pharmaceuticals (Basel, Switzerland)|August 26, 2022
Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase InhibitorsArtem Ovchinnikov, Alexandra Potekhina, Evgeny Belyavskiy, et al.
Journal of Clinical Ultrasound : JCU|May 11, 2019
Right heart masses in a patient with endometrial stromal sarcomaMarijana Tadic, Evgeny Belyavskiy, Cesare Cuspidi, et al.
BMC Cardiovascular Disorders|September 11, 2020
Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot studyEvgeny Belyavskiy, Artem Ovchinnikov, Alexandra Potekhina, et al.
Journal of Clinical Ultrasound : JCU|October 11, 2022
Left atrial dysfunction as the major driver of heart failure with preserved ejection fraction syndromeArtem G Ovchinnikov, Alexandra Potekhina, Evgeny Belyavskiy, et al.
International Journal of Molecular Sciences|May 11, 2024
Use of Statins in Heart Failure with Preserved Ejection Fraction: Current Evidence and PerspectivesArtem Ovchinnikov, Alexandra Potekhina, Tatiana Arefieva, et al.
Journal of Clinical Medicine|June 7, 2019
Sex and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Clinical StudiesMarijana Tadic, Cesare Cuspidi, Sven Plein, et al.
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Therapeutics and Clinical Risk Management|September 9, 2020
Diagnosis and Management of Patients with Heart Failure with Preserved Ejection Fraction (HFpEF): Current Perspectives and RecommendationsOlga Dzhioeva, Evgeny Belyavskiy
Reviews in Cardiovascular Medicine|July 30, 2024
Preoperative Stress Testing before Non-Cardiac SurgeryOlga Dzhioeva, Marijana Tadic, Evgeny Belyavskiy
Pharmacological Research|January 26, 2019
Intriguing relationship between antihypertensive therapy and cancerMarijana Tadic, Cesare Cuspidi, Evgeny Belyavskiy, et al.
Journal of Clinical Medicine|July 9, 2022
Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort StudyArtem Ovchinnikov, Evgeny Belyavskiy, Alexandra Potekhina, et al.
Pharmaceuticals (Basel, Switzerland)|August 26, 2022
Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase InhibitorsArtem Ovchinnikov, Alexandra Potekhina, Evgeny Belyavskiy, et al.
Journal of Clinical Ultrasound : JCU|May 11, 2019
Right heart masses in a patient with endometrial stromal sarcomaMarijana Tadic, Evgeny Belyavskiy, Cesare Cuspidi, et al.
BMC Cardiovascular Disorders|September 11, 2020
Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot studyEvgeny Belyavskiy, Artem Ovchinnikov, Alexandra Potekhina, et al.
Journal of Clinical Ultrasound : JCU|October 11, 2022
Left atrial dysfunction as the major driver of heart failure with preserved ejection fraction syndromeArtem G Ovchinnikov, Alexandra Potekhina, Evgeny Belyavskiy, et al.
International Journal of Molecular Sciences|May 11, 2024
Use of Statins in Heart Failure with Preserved Ejection Fraction: Current Evidence and PerspectivesArtem Ovchinnikov, Alexandra Potekhina, Tatiana Arefieva, et al.
Journal of Clinical Medicine|June 7, 2019
Sex and Heart Failure with Preserved Ejection Fraction: From Pathophysiology to Clinical StudiesMarijana Tadic, Cesare Cuspidi, Sven Plein, et al.
Pageof 5